MGTX

MeiraGTx is a clinical-stage genetic medicines company that, by its own admission in the 10-K, 'has not generated any product revenues to date' and does 'not expect to generate revenue from sales of products unless and until we successfully initiate and complete clinical development and obtain regulatory approval.' The FY2025 'revenue' of $81.4M is therefore not product sales but collaboration/milestone recognition (J&J $130M collab + $125M asset purchase, plus $75M Lilly and $50M Hologen contributions disclosed in the MD&A). That makes the headline +144.6% YoY growth and 11.7x P/S misleading as a fundamentals signal — it is lumpy partner cash, not a recurring commercial run-rate.

The balance sheet is the disqualifier. Stockholders' equity has flipped negative to -$5.79M (YoY -108.5%), accumulated deficit is -$816M, and current liabilities doubled to $123M against just $91.8M of current assets — a working-capital deficit of roughly $31M. Cash and equivalents fell 36.4% to $65.9M (10-K cites $68.2M including restricted), while the company burned $46.4M in operating cash and spent $130M on R&D in FY2025. Even with the improvement in burn (operating cash flow YoY +55.6%), the runway implied by $65.9M of cash against ongoing R&D intensity is roughly 12-18 months at best, and far shorter if partner inflows don't repeat. The MD&A's own framing — 'devoted substantially all of our resources to developing our technology platform' with $637.4M of equity already raised — signals that further dilution is the base-case funding mechanism.